Todd Horiuchi
Pulmonary Disease · Sarasota, FLNPI 1609808161
Payments from drug & device makers
Across 162 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$429
- AstraZeneca$409
- Actelion Pharmaceuticals US, Inc.$371
- Boehringer Ingelheim$180
- Novo Nordisk$177
- Takeda Pharmaceuticals U.S.A., Inc.$161
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,58299%
- Education$100%
- Gifts$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $429 |
| AstraZeneca(2 entities) | 5 | $409 |
| Actelion Pharmaceuticals US, Inc. | 18 | $371 |
| Boehringer Ingelheim | 10 | $180 |
| Novo Nordisk | 11 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $161 |
| Jazz Pharmaceuticals Inc. | 3 | $161 |
| Bayer | 8 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $151 |
| Tetraphase Pharmaceuticals, Inc. | 8 | $150 |
| United Therapeutics Corporation | 1 | $125 |
| Genentech USA, Inc. | 7 | $119 |
| Pfizer | 7 | $113 |
| Philips North America LLC | 5 | $112 |
| GSK | 7 | $100 |
| Lilly USA, LLC | 4 | $90 |
| AbbVie(2 entities) | 4 | $59 |
| Antares Pharma, Inc. | 4 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Novartis | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Shire North American Group Inc | 2 | $39 |
| Aytu Biopharma, Inc. | 3 | $38 |
| Johnson & Johnson | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 2 | $33 |
| IBSA Pharma Inc. | 2 | $32 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Boston Scientific | 1 | $21 |
| Optinose US, Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,601 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 18 | $249,628 |
| MounjaroTirzepatide | 52 | $62,182 |
| EliquisApixaban | 43 | $51,156 |
| Ambrisentan | 13 | $36,823 |
| XifaxanRifaximin | 13 | $36,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,118 |
| GemtesaVibegron | 26 | $14,074 |
| TrulicityDulaglutide | 12 | $13,645 |
| NamzaricMemantine Hcl/Donepezil Hcl | 19 | $12,633 |
| MyrbetriqMirabegron | 20 | $12,483 |
| JardianceEmpagliflozin | 14 | $12,002 |
| EntrestoSacubitril/Valsartan | 16 | $11,519 |
| XareltoRivaroxaban | 12 | $9,896 |
| JanuviaSitagliptin Phosphate | 12 | $8,048 |
| Atorvastatin Calcium | 106 | $1,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $152 | $249,62818 claims |
| Lilly USA, LLCMounjaro, Trulicity | $90 | $75,82764 claims |
| PfizerEliquis | $113 | $51,15643 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $151 | $36,61613 claims |
| GSKTrelegy Ellipta | $100 | $23,11830 claims |
| AbbVieNamzaric, Synthroid | $59 | $14,38842 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $12,48320 claims |
| Boehringer IngelheimJardiance | $180 | $12,00214 claims |
| NovartisEntresto | $44 | $11,51916 claims |
| Johnson & JohnsonXarelto | $36 | $9,89612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Sarasota
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.